Cancer Immunology, Immunotherapy

, Volume 56, Issue 10, pp 1637–1644 | Cite as

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

  • Martin Sebastian
  • Bernward Passlick
  • Hilke Friccius-Quecke
  • Michael Jäger
  • Horst Lindhofer
  • Frank Kanniess
  • Rainer Wiewrodt
  • Eckhard Thiel
  • Roland Buhl
  • Alexander Schmittel
Original Article



Catumaxomab is a trifunctional monoclonal antibody with binding sites directed to human EpCAM and the human T cell antigen CD3 (anti-EpCAM × anti-CD3). Catumaxomab demonstrated efficacy when administered intraperitoneally in patients with EpCAM positive malignant ascites from ovarian cancer in terms of tumor cell killing and reduction of ascites generation. As EpCAM is also overexpressed in NSCLC, the present study was conducted in order to evaluate safety and tolerability of intravenous treatment with catumaxomab.

Patients and methods

UICC stage IB–IV NSCLC patients were eligible, if they had at least one prior therapy. Other inclusion criteria were: age 18–75 years, adequate bone marrow function and AST or gamma-GT ≤ 2.5 ULN. Escalating doses of catumaxomab were administered over 8 h as a continuous intravenous infusion. Dose escalation started at 2 μg and was increased to 7.5 μg. In addition various doses of dexamethasone as premedication were investigated. All patients were pretreated with antihistamines.


Dose limiting toxicity (DLT) was a grade 3 and 4 elevation of ALT, AST and gamma-GT, which was observed in dose level IV (10 mg dexamethasone premedication, 5 μg catumaxomab) and V (40 mg dexamethasone followed by 7.5 μg catumaxomab). Elevated liver enzymes decreased to grade 2 within 3–7 days and were at baseline level within 14 days after infusion. The maximum tolerated dose (MTD) was defined in dose level III (40 mg of dexamethasone followed by 5 μg of catumaxomab).


Five micrograms of catumaxomab with a pre-medication of 40 mg dexamethasone and antihistamines can be recommended as first dose for i.v. therapy consisting of multiple catumaxomab infusions for patients with NSCLC.


Catumaxomab Trifunctional Antibody Anti-EpCAM NSCLC Phase I 


  1. 1.
    Munz M, Zeidler R, Gires O (2005) The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 225:151–157PubMedCrossRefGoogle Scholar
  2. 2.
    Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76:1438–1442PubMedCrossRefGoogle Scholar
  3. 3.
    Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S, Warnaar SO (1995) Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 145:91–122PubMedCrossRefGoogle Scholar
  4. 4.
    Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35:122–128PubMedCrossRefGoogle Scholar
  5. 5.
    Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Krononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135PubMedCrossRefGoogle Scholar
  6. 6.
    Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758PubMedCrossRefGoogle Scholar
  7. 7.
    Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 49:911–917PubMedGoogle Scholar
  8. 8.
    Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261–266PubMedCrossRefGoogle Scholar
  9. 9.
    Jaeger M, Stroehlein MA, Schoberth A, Burges A, Heiss MM, Lindhofer H (2004) Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: results of a phase I/II study. J Clin Oncol 23(Suppl):2504Google Scholar
  10. 10.
    Stroehlein M, Jaeger M, Lindhofer H, Peschel C, Jauch KW, Heiss MM (2004) Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. J Clin Oncol 23(Suppl):2532Google Scholar
  11. 11.
    Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jaminson PM, Wingo PA, Howe HL, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101:3–27PubMedCrossRefGoogle Scholar
  12. 12.
    Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589–2597PubMedCrossRefGoogle Scholar
  13. 13.
    The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360Google Scholar
  14. 14.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DF, ECOG (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98Google Scholar
  15. 15.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRefGoogle Scholar
  16. 16.
    Sandler AB, Gray R, Brahmer J et al (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23:24Google Scholar
  17. 17.
    Carney DN (2002) Lung cancer—time to move on from chemotherapy. N Engl J Med 346:126–128PubMedCrossRefGoogle Scholar
  18. 18.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRefGoogle Scholar
  19. 19.
    Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246–1252PubMedGoogle Scholar
  20. 20.
    Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A (2001) TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499–3503PubMedGoogle Scholar
  21. 21.
    Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526–2534PubMedCrossRefGoogle Scholar
  22. 22.
    Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JM, Colnaghi MI, Canevari S (1999) Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84:62–68PubMedCrossRefGoogle Scholar
  23. 23.
    Azinovic I, Denardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ (2006) Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55:1451–1458PubMedCrossRefGoogle Scholar
  24. 24.
    Molema G, Tervaer JW, Kroesen BJ, Helfrich W, Meijer DK, de Leij LF (2000) CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro. Br J Cancer 82:472–479PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Martin Sebastian
    • 1
  • Bernward Passlick
    • 2
  • Hilke Friccius-Quecke
    • 3
  • Michael Jäger
    • 4
  • Horst Lindhofer
    • 5
  • Frank Kanniess
    • 6
  • Rainer Wiewrodt
    • 1
  • Eckhard Thiel
    • 7
  • Roland Buhl
    • 1
  • Alexander Schmittel
    • 7
  1. 1.III. Medical Clinic, Department of Pulmonary MedicineUniversity of MainzMainzGermany
  2. 2.Department of Thoracic SurgeryUniversity of FreiburgFreiburgGermany
  3. 3.Fresenius Biotech GmbHMunichGermany
  4. 4.TRION Research GmbHMunichGermany
  5. 5.TRION Pharma GmbHMunichGermany
  6. 6.Pulmonary Research InstituteHospital Grosshansdorf, Center for Pneumology and Thoracic SurgeryGrosshansdorfGermany
  7. 7.Department for Haematology, Oncology and Transfusion MedicineCharité Campus Benjamin FranklinBerlinGermany

Personalised recommendations